Loading content…
Affiliate-supportedIndependent editorialWe never sell medicationSee how
Midwest · Indiana
Local context for Wegovy, Ozempic, Mounjaro, and Zepbound in Indianapolis (880,000 residents, 2,140,000 metro). Eli Lilly (Mounjaro and Zepbound manufacturer) is headquartered here; IU Health is the dominant academic system.
Availability and prices vary by pharmacy and date. We do not maintain real-time per-pharmacy stock data. Confirm with pharmacies directly.
Wegovy
semaglutide · Novo Nordisk
Once-weekly semaglutide injection FDA-approved for chronic weight management in adults and adolescents.
Wegovy in Indianapolis →
Ozempic
semaglutide · Novo Nordisk
Once-weekly semaglutide injection FDA-approved for adults with type 2 diabetes.
Ozempic in Indianapolis →
Mounjaro
tirzepatide · Eli Lilly
Once-weekly tirzepatide injection FDA-approved for adults with type 2 diabetes.
Mounjaro in Indianapolis →
Zepbound
tirzepatide · Eli Lilly
Once-weekly tirzepatide injection FDA-approved for chronic weight management and obstructive sleep apnea.
Zepbound in Indianapolis →
Indianapolis is a midwest-region city with a population of 880,000 (2,140,000 in the broader metropolitan area). Indiana expanded Medicaid under the Affordable Care Act, which means low-income adults can typically qualify for GLP-1 coverage for type 2 diabetes if the state Medicaid program lists the drug.
Statewide, notable health systems include Indiana University Health, Community Health Network.
Indiana's Medicaid program is Healthy Indiana Plan / Hoosier Healthwise. Coverage rules for GLP-1 medications vary by drug and indication; see our pricing by state map and payer-coverage guides for details.
Cities of similar size with comparable healthcare markets.